Schedule II

Schedule II is the second-most-restricted tier of the United States Controlled Substances Act (CSA), a federal statute enacted in 1970. A substance placed here is judged to have a high potential for abuse, a currently accepted medical use in the United States, and the potential to produce severe psychological or physical dependence.

The classification is administered by the Drug Enforcement Administration (DEA), in consultation with the Food and Drug Administration (FDA). It is a US federal designation; the same numeral appears in other countries' laws with different meanings and criteria.

What it means in practice

Schedule II imposes constraints that go beyond requiring a prescription. Refills are prohibited; a new written or DEA-compliant electronic prescription is required each time. Prescriptions generally cannot be telephoned to a pharmacy as lower-schedule prescriptions can. Pharmacies and practitioners face strict record-keeping and storage requirements.

For manufacturers, the DEA sets annual aggregate production quotas capping how much of each substance the industry may produce — intended to limit diversion while preserving supply for medical purposes.

Substances enter the schedule through the DEA's administrative rulemaking process, with an FDA evaluation required before final placement. Temporary emergency scheduling is also available. Rescheduling occurs: in 2014, hydrocodone combination products moved from Schedule III to Schedule II, tightening prescription requirements on one of the most widely dispensed opioid formulations in the country.

Research using Schedule II substances is permitted with a DEA researcher registration and is subject to less procedural burden than Schedule I research — the placement licenses and structures clinical investigation rather than prohibiting it.

Examples include most strong opioids, pharmaceutical stimulants such as amphetamine and methylphenidate, cocaine in its narrow clinical role as a topical anaesthetic, methamphetamine, and phencyclidine.

How jurisdictions vary

The numeral II carries no consistent meaning across legal systems. In the United Kingdom, Schedule 2 of the Misuse of Drugs Regulations 2001 covers many of the same compounds — morphine, amphetamine, cocaine — but operates under different criteria and licensing requirements. A substance can appear in a tier labelled 2 in both systems and face different prescribing rules in each.

The United Nations drug treaties — the 1961 Single Convention on Narcotic Drugs and the 1971 Convention on Psychotropic Substances — use their own schedule numbering that does not map onto CSA schedules. Each signatory country implements treaty obligations through national legislation, which may assign a different number entirely.

Canada and Australia each use distinct scheduling frameworks with different numbering conventions. A tier numbered II elsewhere may correspond to a very different US schedule in practical restriction, or to no direct equivalent at all.

What is contested

The scheduling criteria include the phrase currently accepted medical use, which is a legal determination made through the rulemaking process rather than a direct reading of published clinical evidence. The placement reflects a regulatory finding, not a verdict on a drug's overall risk-benefit profile.

Methamphetamine illustrates the distinction: it holds Schedule II status because an FDA-approved formulation exists for attention-deficit disorder and short-term obesity treatment, even though its broader harm profile is widely considered substantial. The phrase high potential for abuse is similarly a regulatory finding — there is no single standardised measurement underlying it — and published research assessments of relative harm have not always aligned neatly with where substances sit in the CSA schedule.

Scope and currency

This entry describes Schedule II as defined under the United States Controlled Substances Act and is not legal advice. It does not reflect the law in any jurisdiction outside the United States, or amendments to the schedule made after August 2025.

Scheduling law is jurisdiction-specific and frequently amended. For the applicable legal status of a particular substance, see that substance's legal status section, which carries its own jurisdiction, date, and source.